All In Biotech

Drug Trial Radar · NCT07863180

Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial

Tributyrin for PSP: Phase 1b Virtual Trial - Feasibility Study

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

May 2027

Study completion May 2027

Sponsor

Lead sponsor
Prabesh KanelAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Farmer Family Foundation
First posted
Oct 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research is studying a supplement called tributyrin in people with Progressive Supranuclear Palsy (PSP) to learn about its safety and tolerability as a potential treatment. The goal of this research study is to see if a similar supplementation regimen and virtual testing is feasible for people with PSP.

Conditions

  • Parkinson Disease
  • Multiple System Atrophy
  • Progressive Supranuclear Palsy(PSP)

Interventions

  • TributyrinDrug

    Post-biotic short chain fatty acid dietary supplement. Participants will take 500mg TID tributyrin supplement for 90 days +/- 7 days.

  • PlaceboDrug

    Participants will take 500mg TID placebo for 90 days +/- 7 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Tolerability of tributyrinTime frame: Visit 7 (approximately day 90)
  2. Safety of tributyrinTime frame: Up to visit 7 (approximately day 90)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Domino's Farms

    Ann Arbor, Michigan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.